Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects

 
• By Sue Sutter
  
Diabetes
Novo's semaglutide picked up a US FDA panel's endorsement for treatment of type 2 diabetes.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip